Merck Collaborates with Seven and Eight BioPharmaceuticals to Evaluate the BDB001 + Keytruda (pembrolizumab) for Advanced Solid Tumors
Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval for 1L Treatment of Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma
Shots:
- The companies collaborate to explore the combination of Seven and Eight’s BDB001 and Merck’s Keytruda (pembrolizumab) for treating patients with advanced solid tumors
- As per the agreement, Seven and Eight BioPharmaceuticals will conduct the clinical study assessing the combination regimen to address the unmet medical needs of patients with advanced and difficult-to-treat tumor types
- BDB001 is an immune modulator targeting TLR 7 & 8 while Keytruda is an anti-PD-1 therapy, act by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells
Click here to read full press release/ article | Ref: Businesswire | Image: Bloomberg